H-E-B plans to offer COVID-19 vaccines once they're available. Photo courtesy of BCM

As a pair of COVID-19 vaccines await emergency-use approval from the U.S. Food and Drug Administration, Texas' largest grocer is prepping for the vaccines' unprecedented rollout.

San Antonio-based H-E-B announced its pharmacies will administer the COVID-19 vaccine to Texans once it's available to the general public.

"At H-E-B, the health and safety of Texans is our top priority," the company noted in a release posted December 3. "As a trusted source for all routine childhood and adult immunizations, H-E-B pharmacies will partner with the federal and state government to administer the COVID-19 vaccine when it becomes available to the general public, following the CDC distribution schedule."

Though it's unclear when H-E-B will receive the vaccine doses and which company's vaccine —Moderna, the Pfizer/BioNTech, or otherwise — will be available through the grocer, health-focused organizations and businesses like H-E-B are preparing for the massive distribution, which could begin as soon as 24 hours after the FDA gives its approval.

The goal of Operation Warp Speed, the federal government's plan to help develop, make, and distribute millions of COVID-19 vaccine doses to Americans, is "to deliver safe vaccines that work, with the first supply becoming available before the end of 2020," according to the Centers for Disease Control and Prevention.

The CDC also notes once a vaccine is approved and released, there may not be enough doses available for all U.S. adults, though supplies will increase over time and "all adults should be able to get vaccinated later in 2021."

The CDC further states that vaccine doses purchased with taxpayer money will be distributed to Americans for free. However, vaccine providers can charge an administration fee for providing the shot.

It's unclear how many doses each store will receive and whether the company plans to distribute the vaccine through its pharmacy drive-thrus, at onsite pop-up medical tents, or solely from its in-store pharmacies.

"We do have all H-E-B pharmacies registered and ready to administer the vaccine," says Leslie Sweet, H-E-B's director of public affairs in the Central Texas region. "We will follow the prescribed allocation schedule as prescribed by [the Department of State Health Services]. We do not yet have a specific date or allocation number to share."

H-E-B pharmacies throughout the state already have some safety measures in place because of COVID-19 concerns, including allowing customers to prepay for prescriptions on the phone prior to picking them up or have their prescriptions delivered for free, and offering no-contact pickup and delivery of prescriptions through its pharmacy drive-thrus.

Additionally, H-E-B says it is continuing to take steps to protect its customers and employees during the pandemic.

"We're going above and beyond our already stringent sanitation standards, cleaning and disinfecting pharmacy counters, waiting areas, and drive-thru surfaces at a higher frequency," the grocer notes in its recent release. "Our pharmacy partners are practicing proper hand-washing throughout the day, and disinfecting and wiping down commonly used surfaces. We've also installed acrylic barriers and provided masks and gloves for all pharmacy partners. … As always, your health and safety is of the utmost importance to us. Together, we can slow the spread."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.